



## Optibrium Appoints Director of Computational Chemistry as Business Expands

*Celebrating growth across all areas on its fifth anniversary as an independent company*

**CAMBRIDGE, UK, 29 April, 2014** – Optibrium™, a developer of software for drug discovery, today announced the appointment of Dr Peter Hunt as Director of Computational Chemistry, as part of further growth across all areas of its business. This success is built on a growing, global customer base for Optibrium's flagship product StarDrop™ within the pharmaceutical industry and its adoption in other chemistry fields including agrochemicals and cosmetics. Optibrium has also recently extended its product portfolio with the introduction of Asteris™, an iPad app that enables researchers to rapidly evaluate new compound ideas when and where they want.

Reflecting the growth in the business, Optibrium has expanded its R&D and operational teams to further accelerate the rate of product innovation and support its rapidly growing customer base. This has required the company to extend its facilities by 50%, less than two years after its last office expansion.

As part of the expansion of the R&D team, Dr Peter Hunt has joined as Director of Computational Chemistry. Peter joins Optibrium from Novartis, where he was Group Leader, Computer Aided Drug Discovery (CADD). Peter has over 25 years of experience in drug discovery, both in industry and academic research, having previously been CADD Group Leader at Merck and the 3D Centre in Australia. Peter will provide leadership on research efforts relating to Optibrium's software and the EU funded HeCaToS project, and his extensive drug discovery experience will further support users of Optibrium's software platforms.

Peter commented, "I am delighted to be joining Optibrium and contributing to the development of the StarDrop product and the research into hepatic and cardiac toxicity estimation funded through the EU. Having been a user of StarDrop for several years, I have been impressed by the usability and intuitive nature of the software and I hope to build on this as we bring new features to StarDrop and Optibrium's growing product portfolio."

Dr Matthew Segall, Optibrium's CEO, added "We are very happy to welcome Peter to our team, which has maintained an impressive rate of innovation over the last 5 years as we expanded our customer base worldwide. The continued growth of Optibrium is a result of the team's hard work and together we look forward to developing new solutions that will help scientists to improve the efficiency and productivity of drug discovery."

For further information on Optibrium, please visit [www.optibrium.com](http://www.optibrium.com), contact [info@optibrium.com](mailto:info@optibrium.com) or call +44 1223 815900.

ENDS

## Notes to Editors:



For high resolution image please email [sarah.jeffery@zymecommunications.com](mailto:sarah.jeffery@zymecommunications.com)

### Media contact

Sarah Jeffery

Zyme Communications

E-mail: [sarah.jeffery@zymecommunications.com](mailto:sarah.jeffery@zymecommunications.com)

Phone: +44 (0) 7771 730919

### Optibrium

Nick Foster

Director, Business Development

E-mail: [nick.foster@optibrium.com](mailto:nick.foster@optibrium.com)

Phone: +44 (0) 1223 815900

### About Optibrium Ltd.

Optibrium provides drug discovery software solutions that bring confidence to the selection and design of high quality candidate drugs. The Company's flagship platform, StarDrop, creates an intuitive, highly visual and flexible environment to facilitate and speed up lead identification and optimisation, quickly targeting effective drug candidates with a high probability of success downstream. Asteris™ is an iPad app, developed as a technology collaboration with Integrated Chemistry Design, combining highly intuitive chemistry drawing tools with StarDrop's visually informative predictive modelling. Asteris enables researchers the rapidly evaluate new compound ideas when and where they want.

Founded in 2009, Optibrium continues to develop new products and research novel technologies to improve the efficiency and productivity of the drug discovery process. Optibrium works closely with its broad range of customers and collaborators that include leading global pharma, agrochemical and flavouring companies, biotech and academic groups.

Visit the online community at <http://www.optibrium.com/community/> for further discussions on improving the productivity of drug discovery.